Drug Patents owned by Msd Merck Co

1. List of Delstrigo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603282 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(13 years from now)

US10842751 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 30, 2023
New Indication (I) Sep 19, 2022
New Patient Population (NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: Treatment of hiv-1 infection in adult patients as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to the individual components of delstrigo; For the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; Treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed

Dosage: TABLET;ORAL

How can I launch a generic of DELSTRIGO before it's patent expiration?
More Information on Dosage

2. List of Emend drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(4 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of EMEND before it's patent expiration?
More Information on Dosage

3. List of Pifeltro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 30, 2023
New Indication (I) Sep 19, 2022
New Patient Population (NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: For use in combination with other antiretroviral agents for the treatment of hiv-1 as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to doravirine; For use in combination with other antiretroviral agents for the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen if virologically suppressed

Dosage: TABLET;ORAL

More Information on Dosage

4. List of Recarbrio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 16, 2024
Generating Antibiotic Incentives Now (GAIN) Jul 16, 2029

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: July, 2028

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urinary tract infections, including pyelonephritis (cuti)

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in